|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16/09 | Vericel Corporation Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 02:35 PM | |
| 31/07 | Truist Raises Price Target on Vericel to $58 From $54, Keeps Buy Rating | MT |
| Market Cap | 2.05B 1.81B 1.71B 1.55B 2.92B 197B 2.95B 20.5B 7.89B 101B 7.71B 7.54B 323B | P/E 2026 * |
72.7x | P/E 2027 * | 45.6x |
|---|---|---|---|---|---|
| Enterprise Value | 2.05B 1.81B 1.71B 1.55B 2.92B 197B 2.95B 20.5B 7.89B 101B 7.71B 7.54B 323B | EV / Sales 2026 * |
6.11x | EV / Sales 2027 * | 5.23x |
| Free-Float |
98.81% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aastrom Biosciences Inc
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 01/03/2013 | |
Joseph Mara
DFI | Director of Finance/CFO | 51 | 25/01/2021 |
| Chief Tech/Sci/R&D Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Alan Rubino
BRD | Director/Board Member | 71 | 28/09/2005 |
Robert Zerbe
CHM | Chairman | 75 | 05/10/2012 |
Heidi Hagen
BRD | Director/Board Member | 57 | 23/08/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.33% | +0.53% | +51.65% | +115.42% | 1,056B | |
| -1.06% | -1.65% | +42.78% | +69.98% | 645B | |
| -0.65% | -1.32% | +12.98% | +75.49% | 465B | |
| -2.66% | -1.87% | +73.13% | +41.15% | 368B | |
| -0.06% | -3.88% | +34.32% | +39.39% | 335B | |
| -0.79% | +2.01% | +19.82% | +27.79% | 275B | |
| -1.19% | -1.21% | +9.82% | +10.61% | 255B | |
| -0.50% | +3.80% | +49.37% | +56.84% | 229B | |
| -1.47% | -1.53% | +34.28% | +98.89% | 188B | |
| Average | -0.84% | -0.18% | +36.46% | +59.51% | 423.98B | |
| Weighted average by Cap. | -1.02% | -0.23% | +39.91% | +71.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 336M 296M 281M 253M 477M 32.24B 483M 3.36B 1.29B 16.48B 1.26B 1.23B 52.84B | 393M 346M 328M 296M 558M 37.67B 565M 3.92B 1.51B 19.26B 1.48B 1.44B 61.75B |
| Net income | 29.29M 25.79M 24.44M 22.06M 41.58M 2.81B 42.12M 292M 113M 1.44B 110M 108M 4.6B | 47.29M 41.64M 39.45M 35.62M 67.13M 4.53B 68M 472M 182M 2.32B 178M 174M 7.43B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
